OpenLB
Open Library of Bioscience
Advanced Search
Vox sanguinis
Apr, 2008;94 (3): 202-208.

Platelet-rich plasma and platelet gel preparation using Plateltex.

L Mazzucco, V Balbo, E Cattana, P Borzini
Author Information
  1. L Mazzucco: Blood Transfusion Centre and Biotechnology Laboratory, Ospedale SS Antonio e Biagio, Alessandria, Italy.
  2. V Balbo: Blood Transfusion Centre and Biotechnology Laboratory, Ospedale SS Antonio e Biagio, Alessandria, Italy.
  3. E Cattana: Blood Transfusion Centre and Biotechnology Laboratory, Ospedale SS Antonio e Biagio, Alessandria, Italy.
  4. P Borzini: Blood Transfusion Centre and Biotechnology Laboratory, Ospedale SS Antonio e Biagio, Alessandria, Italy.
PMID: 18179680 DOI: 10.1111/j.1423-0410.2007.01027.x

Abstract

BACKGROUND: The platelet gel is made by embedding concentrate platelets within a semisolid (gel) network of polymerized fibrin. It is believed that this blood component will be used more and more in the treatment of several clinical conditions and as an adjunctive material in tissue engineering. Several systems are available to produce platelet-rich plasma (PRP) for topical therapy. Recently, a new system became commercially available, Plateltex. Here we report the technical performance of this system in comparison with the performance of other commercially available systems: PRGF, PRP-Landesber, Curasan, PCCS, Harvest, Vivostat, Regen and Fibrinet.
MATERIAL AND METHODS: Both the PRP and the gel were prepared according to the manufacturer's directions. The blood samples of 20 donors were used. The yield, the efficiency, and the amount of platelet-derived growth factor AB (PDGF-AB), transforming growth factor beta, vascular endothelial growth factor and fibroblast growth factor were measured in the resulting PRP. The feature of the batroxobin-induced gelation was evaluated.
RESULTS: The yield, the collection efficiency and the growth factor content of Plateltex were comparable to those of most of the other available systems. The gelation time was not dependent on the fibrinogen concentration; however, it was strongly influenced by the contact surface area of the container where the clotting reaction took place (P < 0.0001).
CONCLUSIONS: Plateltex provided platelet recovery, collection efficiency and PDGF-AB availability close to those provided by other systems marketed with the same intended use. Batroxobin, the enzyme provided to induce gelation, acts differently from thrombin, which is used by most other systems. Platelets treated with thrombin become activated; they release their growth factors quickly. Furthermore, thrombin-platelet interaction is a physiological mechanism that hastens the clot-retraction rate. On the contrary, platelets treated with batroxobin do not become activated; they are passively entrapped within the fibrin network, and their growth factor release occurs slowly. In these conditions, the clot retraction takes longer to occur. According to these differences between thrombin and batroxobin, it is expected that batroxobin-induced PRP activation will tailor slow release of the platelet content, thus, providing longer in loco availability of trophic factors. In selected clinical conditions, this durable anabolic factor availability might be preferable to quick thrombin-induced growth factor release.

References

  1. Jameson CA: Autologous platelet concentrate for the production of platelet gel. Lab Med 2007; 38:39-42
  2. Everts PA, Jakimowicz JJ, Van Beek M, Schönberger JPAM, Devilee RJJ, Overdevest EP, Knape JTA, Van Zundert A: Reviewing the structural features of autologous platelet-leukocyte gel and suggestions for use in surgery. Eur Surg Res 2007; 39:199-207
  3. Lindeboom JA, Mathura KR, Aartman IH, Kroon FH, Milstein DM, Ince C: Influence of the application of platelet-enriched plasma in oral mucosal wound healing. Clin Oral Implants Res 2007; 18:133-139
  4. Hom DB, Linzie MB, Huang TC: The healing effects of autologous platelet gel on acute human skin wounds. Arch Facial Plast Surg 2007; 9:174-183
  5. Al-Sukhun J, Helenius M, Lindqvist C, Thören H: Use of platelet rich plasma (PRP) in the reconstruction of mandibular bony defects: Clinical and radiographic follow-up. Br J Oral Maxillofac Surg 2007, Epub ahead of print, doi:10.1016/j.bjoms.2006.12.003
  6. Everts PA, Devilee RJ, Oosterbos CJ, Mahoney CB, Schattenkerk ME, Knape JT, Van Zundert A: Autologous platelet gel and fibrin sealant enhance the efficacy of total knee arthroplasty: improved range of motion, decreased length of stay and a reduced incidence of arthrofibrosis. Knee Surg Sports Traumatol Arthrosc 2007; 5:888-894
  7. Mazzucco L, Medici D, Serra M, Panizza R, Rivara G, Orecchia S, Libener R, Cattana E, Levis A, Betta PB, Borzini P: The use of autologous platelet-gel to treat difficult-to-heal wounds: a pilot study. Transfusion 2004; 44:1013-1018
  8. Kevy SV, Jacobson MS: Comparison of methods for point of care preparation of autologous platelet gel. J Extra Corpor Technol 2004; 36:28-35
  9. Borzini P, Mazzucco L: Tissue regeneration and in loco administration of platelet derivatives: clinical outcome, heterogeneous products, and heterogeneity of the effector mechanisms. Transfusion 2005; 35:1759-1767
  10. Leitner GC, Gruber R, Neumuller J, Wagner A, Kloimstein P, Hocker P, Kormoczi GF, Buchta C: Platelet content and growth factor release in platelet-rich plasma: a comparison of four different systems. Vox Sang 2006; 91:135-139
  11. Everts PA, Brown Mahoney C, Hoffmann JJ, Schonberger JP, Box HA, Van Zundert A, Knape JT: Platelet-rich plasma preparation using three devices: implications for platelet activation and platelet growth factor release. Growth Factors 2006; 24:165-171
  12. Weibrich G, Kleis WK, Hitzler WE, Hafner G: Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasma: a technical report. Int J Oral Maxillofac Implants 2005; 20:118-123
  13. Weibrich G, Kleis WK, Hafner G: Growth factor levels in the platelet-rich plasma produced by 2 different methods: curasan-type PRP kit versus PCCS PRP system. Int J Oral Maxillofac Implants 2002; 17:184-190
  14. Landesberg R, Roy M, Glickman RS: Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation. J Oral Maxillofac Surg 2000; 58:297-300
  15. Weibrich G, Hansen T, Kleis W, Buch R, Hitzler WE: Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone 2004; 34:665-667
  16. Caplan AI: Mesenchymal stem cells: cell-based reconstructive therapy in orthopedics. Tissue Eng 2005; 7:1198-1211
  17. Du Toit DF, Kleintjes WG, Otto MJ, Mazyala EJ, Page BJ: Soft and hard-tissue augmentation with platelet-rich plasma: tissue culture dynamics, regeneration and molecular biology perspective. Int J Shoulder Surg 2007; 1:64-73
  18. Weibrich G, Kleis WK, Hafner G, Hitzler WE, Wagner W: Comparison of platelet, leukocyte, and growth factor levels in point-of-care platelet-enriched plasma, prepared using a modified Curasan kit, with preparations received from a local blood bank. Clin Oral Implants Res 2003; 14:357-362
  19. Weibrich G, Kleis WK, Buch R, Hitzler WE, Hafner G: The harvest smart PRePTM system versus the Friadent-Schutze platelet-rich plasma kit. Clin Oral Implants Res 2003; 14:233-239
  20. Borzini P, Mazzucco L, Giampaolo A, Hassan HJ: Platelet gel - the Italian way: a call for procedure standardization and quality control. Transfus Med 2006; 16:303-304
  21. Borzini P, Mazzucco L: Platelet-rich plasma (PRP) and platelet derivatives for topical therapy. What is true from the biological view point? ISBT Science Series 2007; 2:272-281
  22. Currie LJ, Sharpe JR, Martin R: The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review. Plast Reconstr Surg 2001; 108:1713-1726
  23. Hantgan R, Fowler W, Erickson H, Hermans J: Fibrin assembly: a comparison of electron microscopic and light scattering results. Thromb Haemost 1980; 44:119-124
  24. Stocker K, Fischer H, Meier J: Thrombin-like snake venom proteinases. Toxicon 1982; 20:265-273
  25. Zehnder JL, Leung LLK: Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76:2011-2016
  26. Niewiaroswki S, Stewart GJ, Nath N, Sha TA, Liverman E: ADP, thrombin, and Bathros atrox thombin-like enzyme in platelet-dependent clot reaction. Am J Physiol 1980; 229:737-745
  27. Hantgan RR, Taylor RG, Lewis JC: Platelets interact with fibrin only after activation. Blood 1985; 65:1299-1311
  28. Kubisz P, Suranova J: Reptilase clot retraction test. Its cofactors and relation to other platelet functions. Pathol Biol (Paris) 1975; 23:269-275
  29. De Clerck F, Borges M, De Gaetano G, Vernvien J: Dissociation of clot retraction from platelet granule fusion and degranulation: an ultrastructural study of Reptilase-human platelet-rich plasma clots. Br J Haematol 1975; 29:341-348
  30. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJJ, Mouhyi J, Gogly B: Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101:E45-E50
  31. Tsay RC, Vo J, Burke A, Eisig SB, Lu HH, Landesberg R: Differential growth factor retention by platelet-rich plasma composites. J Oral Maxillofac Surg 2005; 63:521-528

MeSH Term

Batroxobin
Biotechnology
Blood Component Removal
Blood Platelets
Gels
Growth Substances
Humans
Platelet Count
Platelet Transfusion
Platelet-Derived Growth Factor
Platelet-Rich Plasma
Tissue Engineering

Chemicals

Gels
Growth Substances
Platelet-Derived Growth Factor
platelet-derived growth factor AB
Batroxobin
Comparative Study Evaluation Study Journal Article
Article has an altmetric score of 4

Word Cloud

Created with Highcharts 10.0.0growthfactorplateletgelsystemsavailablePRPPlateltexreleaseusedconditionsefficiencygelationprovidedavailabilitythrombinplateletswithinnetworkfibrinbloodwillclinicalplasmasystemcommerciallyperformanceyieldPDGF-ABbatroxobin-inducedcollectioncontenttreatedbecomeactivatedfactorsbatroxobinlongerBACKGROUND:madeembeddingconcentratesemisolidpolymerizedbelievedcomponenttreatmentseveraladjunctivematerialtissueengineeringSeveralproduceplatelet-richtopicaltherapyRecentlynewbecamereporttechnicalcomparisonsystems:PRGFPRP-LandesberCurasanPCCSHarvestVivostatRegenFibrinetMATERIALANDMETHODS:preparedaccordingmanufacturer'sdirectionssamples20donorsamountplatelet-derivedABtransformingbetavascularendothelialfibroblastmeasuredresultingfeatureevaluatedRESULTS:comparabletimedependentfibrinogenconcentrationhoweverstronglyinfluencedcontactsurfaceareacontainerclottingreactiontookplaceP<00001CONCLUSIONS:recoveryclosemarketedintendeduseBatroxobinenzymeinduceactsdifferentlyPlateletsquicklyFurthermorethrombin-plateletinteractionphysiologicalmechanismhastensclot-retractionratecontrarypassivelyentrappedoccursslowlyclotretractiontakesoccurAccordingdifferencesexpectedactivationtailorslowthusprovidinglocotrophicselecteddurableanabolicmightpreferablequickthrombin-inducedPlatelet-richpreparationusing

Similar Articles

Cited By